New research into a drug to treat a particularly deadly form of children’s cancer could lead to better outcomes for patients.
Dr. Giselle Sholler of Helen DeVos Children’s Hospital in Grand Rapids published the report on a drug called DFMO used to treat neuroblastoma, a childhood cancer with a long-term survival rate of just 50-percent.
Sholler says 13 of the 20 children who participated in the drug trial were able to stabilize their disease.
Three of them are now long-term survivors.